EXAGEN INC (XGN) Fundamental Analysis & Valuation

NASDAQ:XGN • US30068X1037

Current stock price

2.7 USD
+0.02 (+0.75%)
Last:

This XGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. XGN Profitability Analysis

1.1 Basic Checks

  • XGN had negative earnings in the past year.
  • XGN had a negative operating cash flow in the past year.
  • XGN had negative earnings in each of the past 5 years.
  • In the past 5 years XGN always reported negative operating cash flow.
XGN Yearly Net Income VS EBIT VS OCF VS FCFXGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • With a decent Return On Assets value of -34.39%, XGN is doing good in the industry, outperforming 60.08% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -114.34%, XGN is doing worse than 60.27% of the companies in the same industry.
Industry RankSector Rank
ROA -34.39%
ROE -114.34%
ROIC N/A
ROA(3y)-36.6%
ROA(5y)-37.31%
ROE(3y)-125.72%
ROE(5y)-104.06%
ROIC(3y)N/A
ROIC(5y)N/A
XGN Yearly ROA, ROE, ROICXGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400 600

1.3 Margins

  • With a decent Gross Margin value of 58.28%, XGN is doing good in the industry, outperforming 76.16% of the companies in the same industry.
  • In the last couple of years the Gross Margin of XGN has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for XGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.54%
GM growth 5Y-0.76%
XGN Yearly Profit, Operating, Gross MarginsXGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. XGN Health Analysis

2.1 Basic Checks

  • XGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for XGN has been increased compared to 1 year ago.
  • Compared to 5 years ago, XGN has more shares outstanding
  • XGN has a better debt/assets ratio than last year.
XGN Yearly Shares OutstandingXGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
XGN Yearly Total Debt VS Total AssetsXGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • XGN has an Altman-Z score of -5.56. This is a bad value and indicates that XGN is not financially healthy and even has some risk of bankruptcy.
  • XGN's Altman-Z score of -5.56 is on the low side compared to the rest of the industry. XGN is outperformed by 65.70% of its industry peers.
  • XGN has a Debt/Equity ratio of 1.39. This is a high value indicating a heavy dependency on external financing.
  • XGN's Debt to Equity ratio of 1.39 is on the low side compared to the rest of the industry. XGN is outperformed by 78.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.39
Debt/FCF N/A
Altman-Z -5.56
ROIC/WACCN/A
WACC10.79%
XGN Yearly LT Debt VS Equity VS FCFXGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 3.45 indicates that XGN has no problem at all paying its short term obligations.
  • XGN's Current ratio of 3.45 is in line compared to the rest of the industry. XGN outperforms 42.44% of its industry peers.
  • XGN has a Quick Ratio of 3.45. This indicates that XGN is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.45, XGN perfoms like the industry average, outperforming 44.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.45
Quick Ratio 3.45
XGN Yearly Current Assets VS Current LiabilitesXGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. XGN Growth Analysis

3.1 Past

  • XGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.75%.
  • The Revenue has grown by 19.65% in the past year. This is quite good.
  • Measured over the past years, XGN shows a quite strong growth in Revenue. The Revenue has been growing by 9.66% on average per year.
EPS 1Y (TTM)-6.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)19.65%
Revenue growth 3Y13.48%
Revenue growth 5Y9.66%
Sales Q2Q%21.79%

3.2 Future

  • Based on estimates for the next years, XGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.44% on average per year.
  • The Revenue is expected to grow by 8.81% on average over the next years. This is quite good.
EPS Next Y15.36%
EPS Next 2Y21.38%
EPS Next 3Y16.99%
EPS Next 5Y18.44%
Revenue Next Year7.07%
Revenue Next 2Y10%
Revenue Next 3Y10.46%
Revenue Next 5Y8.81%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
XGN Yearly Revenue VS EstimatesXGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
XGN Yearly EPS VS EstimatesXGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. XGN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for XGN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XGN Price Earnings VS Forward Price EarningsXGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XGN Per share dataXGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as XGN's earnings are expected to grow with 16.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.38%
EPS Next 3Y16.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XGN Dividend Analysis

5.1 Amount

  • No dividends for XGN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XGN Fundamentals: All Metrics, Ratios and Statistics

EXAGEN INC

NASDAQ:XGN (4/24/2026, 8:14:58 PM)

2.7

+0.02 (+0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10
Earnings (Next)05-12
Inst Owners52.66%
Inst Owner Change0.11%
Ins Owners8.92%
Ins Owner Change10.73%
Market Cap64.94M
Revenue(TTM)66.58M
Net Income(TTM)-19.95M
Analysts83.64
Price Target10.03 (271.48%)
Short Float %9.48%
Short Ratio4.39
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.55%
Min EPS beat(2)-94.88%
Max EPS beat(2)-4.22%
EPS beat(4)1
Avg EPS beat(4)-30.81%
Min EPS beat(4)-94.88%
Max EPS beat(4)1.81%
EPS beat(8)5
Avg EPS beat(8)0.88%
EPS beat(12)9
Avg EPS beat(12)11.45%
EPS beat(16)11
Avg EPS beat(16)8.44%
Revenue beat(2)1
Avg Revenue beat(2)0.22%
Min Revenue beat(2)-0.61%
Max Revenue beat(2)1.05%
Revenue beat(4)3
Avg Revenue beat(4)2.61%
Min Revenue beat(4)-0.61%
Max Revenue beat(4)5.51%
Revenue beat(8)5
Avg Revenue beat(8)2.74%
Revenue beat(12)9
Avg Revenue beat(12)9.55%
Revenue beat(16)12
Avg Revenue beat(16)11.66%
PT rev (1m)-21.78%
PT rev (3m)-33.17%
EPS NQ rev (1m)-1.45%
EPS NQ rev (3m)-37.25%
EPS NY rev (1m)-55.15%
EPS NY rev (3m)-58.4%
Revenue NQ rev (1m)-0.62%
Revenue NQ rev (3m)-7.04%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-7.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.98
P/FCF N/A
P/OCF N/A
P/B 3.72
P/tB 3.72
EV/EBITDA N/A
EPS(TTM)-0.89
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS2.77
BVpS0.73
TBVpS0.73
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -34.39%
ROE -114.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.28%
FCFM N/A
ROA(3y)-36.6%
ROA(5y)-37.31%
ROE(3y)-125.72%
ROE(5y)-104.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.54%
GM growth 5Y-0.76%
F-Score3
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity 1.39
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.26%
Cap/Sales 0.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.45
Quick Ratio 3.45
Altman-Z -5.56
F-Score3
WACC10.79%
ROIC/WACCN/A
Cap/Depr(3y)32.78%
Cap/Depr(5y)126%
Cap/Sales(3y)1.15%
Cap/Sales(5y)3.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y15.36%
EPS Next 2Y21.38%
EPS Next 3Y16.99%
EPS Next 5Y18.44%
Revenue 1Y (TTM)19.65%
Revenue growth 3Y13.48%
Revenue growth 5Y9.66%
Sales Q2Q%21.79%
Revenue Next Year7.07%
Revenue Next 2Y10%
Revenue Next 3Y10.46%
Revenue Next 5Y8.81%
EBIT growth 1Y-3.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.27%
EBIT Next 3Y30.26%
EBIT Next 5Y20.96%
FCF growth 1Y-3.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.61%
OCF growth 3YN/A
OCF growth 5YN/A

EXAGEN INC / XGN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for EXAGEN INC?

ChartMill assigns a fundamental rating of 2 / 10 to XGN.


What is the valuation status for XGN stock?

ChartMill assigns a valuation rating of 0 / 10 to EXAGEN INC (XGN). This can be considered as Overvalued.


What is the profitability of XGN stock?

EXAGEN INC (XGN) has a profitability rating of 1 / 10.


What is the financial health of EXAGEN INC (XGN) stock?

The financial health rating of EXAGEN INC (XGN) is 3 / 10.